MedTrace Logo

Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients

NCT01744587 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2025-08-15

No results posted yet for this study

Summary

The purpose of this study is to investigate the EBV reactivation rate in post-radiation and remission NPC patients, evaluate the safety and tolerance of EGCG and analyze the observational correlation between EBV reactivation and clinical outcome.

Conditions

Interventions

OTHER

Epigallocatechin Gallate (EGCG)

EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.

DIETARY_SUPPLEMENT

Placebo

Placebo qd (2# bid) for 3 years

Sponsors & Collaborators

  • Mackay Memorial Hospital

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • National Taiwan University Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Tsang Wu Liu, MD · Taiwan Cooperative Oncology Group, National Health Research Institutes

  • Jin Ch Lin, MD PHD · Taichung Veterans General Hospital

  • Jen Ya Chen, PHD · National Institute of Cancer Research, National Health Research Institutes

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2023-05-16
Completion
2023-05-16

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01744587 on ClinicalTrials.gov